Prognostic markers for CAR-T cell therapy in patients with relapsed/refractory multiple myeloma

被引：0
|
作者：
Liu, Yang [1 ]
Yan, Zhiling [2 ]
Wu, Qingyun [2 ]
Chen, Chong [2 ]
Cao, Jiang [2 ]
Li, Zhenyu [2 ]
Xu, Kailin [2 ]
机构：
[1] Xuzhou Med Univ, Dept Hematol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Blood Dis Inst, Xuzhou, Jiangsu, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-029
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [21] Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
    Samer Al Hadidi
    Aniko Szabo
    Jean Esselmann
    Lindsay Hammons
    Munawwar Hussain
    Yetunde Ogunsesan
    Nishanth Thalambedu
    Fatima Khan
    Jaskirat Sethi
    Abhishek Janardan
    Sabarinath Venniyil Radhakrishnan
    Sharmilan Thanendrarajan
    Carolina Schinke
    Binod Dhakal
    Siegfried Janz
    Saurabh Chhabra
    Anita D’Souza
    Maurizio Zangari
    Frits van Rhee
    Meera Mohan
    Bone Marrow Transplantation, 2023, 58 : 443 - 445
  • [22] A suggestion to improve the results of “Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma”
    Majid Arash
    Clinical and Experimental Medicine, 24 (1)
  • [23] Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
    Feng, Deming
    Sun, Jian
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (02)
  • [24] A new CAR-T cell therapy for multiple myeloma
    Hosen, Naoki
    CANCER SCIENCE, 2022, 113 : 644 - 644
  • [25] A Preliminary Study on the Safety and Efficacy of a Novel Human BCMATargeting CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma
    Wang, Yi
    Gao, Ying
    Wang, Hui
    Zhang, Ding
    Zheng, Yan
    Hu, Xingxing
    Gao, Qiuying
    Niu, Ben
    Zhang, Hong
    Zhou, Wei
    Zhang, Weihua
    Ru, Xingli
    Wang, Fangyuan
    BLOOD, 2021, 138
  • [26] Exploring ctDNA as a prognostic marker in patients with Relapsed/Refractory aggressive lymphomas treated with CAR-T cell therapy
    Versteegen, T.
    Khouja, M.
    Chitadze, G.
    Nakov, P.
    Klapper, W.
    Brueggemann, M.
    Iaccarino, I.
    Stoelzel, F.
    Schub, N.
    Baldus, C. D.
    Pott, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 302 - 302
  • [27] Cost per Responder Analysis to Assess the Value of CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
    Martin, Thomas
    Usmani, Saad Z.
    Joseph, Nedra
    Crivera, Concetta
    Valluri, Satish
    Jackson, Carolyn C.
    Cohen, Lucas
    Singh, Sumeet
    Jagannath, Sundar
    BLOOD, 2021, 138
  • [28] BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
    Yuhan Yan
    Yixuan Tu
    Qian Cheng
    Jian Zhang
    Erhua Wang
    Zuqun Deng
    Yan Yu
    Liwen Wang
    Rui Liu
    Ling Chu
    Liqing Kang
    Jing Liu
    Xin Li
    Journal of Translational Medicine, 22 (1)
  • [29] GPRC5D-targeted CAR-T cell therapy in patients with relapsed or refractory multiple myeloma progressing after or refractory to BCMA CAR-T cell therapy: updated eesults from a phase 2 clinical trial
    Xia, Jieyun
    Li, Zhenyu
    Li, Hujun
    Yan, Zhiling
    Xu, Mengdi
    Xu, Kailin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S5 - S6
  • [30] Total Car-T Cost of Care Beyond the Price of Car-T Cell Therapy in Patients with Multiple Myeloma
    Jagannath, Sundar
    Joseph, Nedra
    Crivera, Concetta
    Jackson, Carolyn C.
    Valluri, Satish
    Cost, Patricia
    Phelps, Hilary
    Slowik, Rafal
    Klein, Timothy
    Yu, Xueting
    Smolen, Lee
    Cohen, Adam D.
    BLOOD, 2021, 138
12345